-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

Benzinga·10/30/2026 17:22:03
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.